Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
No Association Between NSAID Exposure and PSP
Parkinsonism Relat Disord; ePub 2017 Dec 6; Marras, et al
The results of a recent study do not suggest an important association between non-steroidal anti-inflammatory drug (NSAID) use and progressive supranuclear palsy (PSP) occurrence or expression. The ENGENE-PSP multicenter case-control study recruited incident PSP cases (n=276) who met the NINDS-PSP Society diagnostic criteria and age-, sex- and race-matched controls (n=278) primarily from the same geographical areas. All subjects underwent standardized interviews to obtain data on demographics, residential history, medication history, and lifetime occupational history. NSAID use was specifically queried by telephone interview using a standardized questionnaire. Researchers found:
- No association was found between NSAID exposure and risk of PSP, age at onset or rate of change of UPDRS motor subscale, PSP Rating Scale, or Mattis Dementia Rating Scale scores.
- This lack of association persisted when NSAID exposure was measured considering any NSAIDs, ibuprofen only, ASA only, or non-ibuprofen, non-aspirin NSAIDs.
Marras C, Cunningham CR, Hou J, et al. Anti-inflammatory drug use and progressive supranuclear palsy. [Published online ahead of print December 6, 2017]. Parkinsonism Relat Disord. doi:10.1016/j.parkreldis.2017.11.346.